Whole-body (18)F-FDG PET identifies high-risk myeloma.

UNLABELLED The purpose of this study was to evaluate the clinical utility of whole-body PET with (18)F-FDG in patients with multiple myeloma and related monoclonal diseases. METHODS Between July 1, 1996, and July 2000, 98 (18)F-FDG PET scans were obtained for 66 patients, with 25 patients having 2 or more scans. The results were compared with routine clinical and staging information, including CT and MRI scans, as indicated. Of the 66 patients, 16 had previously untreated active myeloma, 14 had monoclonal gammopathy of undetermined significance (MGUS), 10 had disease in remission, and 26 had relapsing disease. RESULTS Negative whole-body (18)F-FDG PET findings reliably predicted stable MGUS. Of the 14 MGUS patients with follow-up of 3-43+ mo, myeloma has developed in only 1 (7%), at 8 mo. Conversely, the 16 previously untreated patients with active myeloma all had focal or diffusely positive scan findings. Four (25%) of 16 previously untreated patients with positive (18)F-FDG PET findings had negative full radiologic surveys. Another 4 (25%) of 16 patients had focal extramedullary disease. This was confirmed by biopsy or other imaging techniques. Extramedullary uptake also occurred in 6 (23%) of 26 patients with relapse. This extramedullary uptake was a very poor prognostic factor both before treatment and at relapse. For example, median survival was 7 mo for patients with disease relapse. Persistent positive (18)F-FDG PET findings after induction therapy predicted early relapse. In 13 (81%) of 16 patients with relapsing disease, new sites of disease were identified. The (18)F-FDG PET results were especially helpful in identifying focal recurrent disease in patients with nonsecretory or hyposecretory disease amenable to local irradiation therapy, which was used in 6 patients. CONCLUSION Whole-body (18)F-FDG PET provides important prognostic information, which is clinically useful and complementary to conventional methods of evaluating plasma cell disorders. (18)F-FDG PET is a unique tool for evaluation of nonsecretory myeloma. Residual or recurrent disease after therapy, especially extramedullary disease, is a poor prognostic factor.

[1]  Terry M Therneau,et al.  A long-term study of prognosis in monoclonal gammopathy of undetermined significance. , 2002, The New England journal of medicine.

[2]  Paul J. van Diest,et al.  Biologic correlates of 18fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography , 2002 .

[3]  W. Oyen,et al.  Value of positron emission tomography with [F-18]fluorodeoxyglucose in patients with colorectal liver metastases: a prospective study. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  Yukiko Arisaka,et al.  18F-FDG uptake as a biologic prognostic factor for recurrence in patients with surgically resected non-small cell lung cancer. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[5]  V. Diehl,et al.  Thoracic positron emission tomography using 18F-fluorodeoxyglucose for the evaluation of residual mediastinal Hodgkin disease. , 2001, Blood.

[6]  R. Tucker,et al.  Impact of fluorine-18 fluorodeoxyglucose positron emission tomography on patient management: first year's experience in a clinical center. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  P. Dupont,et al.  Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin's lymphoma: is [18F]FDG-PET a valid alternative to conventional diagnostic methods? , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  S. Reske,et al.  Grading of tumors and tumorlike lesions of bone: evaluation by FDG PET. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[9]  P. Dupont,et al.  Utility of positron emission tomography for the staging of patients with potentially operable esophageal carcinoma. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  L. Griffeth,et al.  PET Emerges as Clinical Oncologic Tool , 1999 .

[11]  A. Guermazi,et al.  Prognostic value of vertebral lesions detected by magnetic resonance imaging in patients with stage I multiple myeloma , 1999, British journal of haematology.

[12]  I. Jinnai,et al.  Magnetic resonance imaging patterns in patients with multiple myeloma , 1997, British journal of haematology.

[13]  S. Larson,et al.  Technetium-99m-MIBI versus fluorine-18-FDG in diffuse multiple myeloma. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[14]  B. Maldague,et al.  Stage I multiple myeloma: value of MR imaging of the bone marrow in the determination of prognosis. , 1996, Radiology.

[15]  Scott T. Grafton,et al.  PET and [18F]-FDG in oncology: a clinical update. , 1996, Nuclear medicine and biology.

[16]  M. Dimopoulos,et al.  Multiple myeloma: MR patterns of response to treatment. , 1994, Radiology.

[17]  M. Dimopoulos,et al.  Risk of disease progression in asymptomatic multiple myeloma. , 1993, The American journal of medicine.

[18]  L G Strauss,et al.  The applications of PET in clinical oncology. , 1991, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[19]  R. Bataille,et al.  Therapeutic implications of myeloma staging * , 1989, European journal of haematology. Supplementum.

[20]  W A Murphy,et al.  Bone marrow imaging. , 1988, Radiology.

[21]  R. Kyle,et al.  Computed tomography in diagnosis and management of multiple myeloma and its variants. , 1985, Archives of internal medicine.

[22]  R A McLeod,et al.  Multiple myeloma: evaluation by CT. , 1985, Radiology.

[23]  V. Devita,et al.  Cancer : Principles and Practice of Oncology , 1982 .

[24]  F. Singer,et al.  Radiographic and radionuclide imaging in multiple myeloma: the role of gallium scintigraphy: concise communication. , 1981, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[25]  J. Woolfenden,et al.  Comparison of bone scintigraphy and radiography in multiple myeloma. , 1980, Radiology.

[26]  S. Salmon,et al.  A clinical staging system for multiple myeloma correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival , 1975, Cancer.

[27]  O. Cope,et al.  Multiple myeloma. , 1948, The New England journal of medicine.